Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
25 September 2013
25 September 2013 - Gide advises the Servier Group on its voluntary public offer of 358 million euros for all outstanding shares of Egis Pharmaceuticals Plc.
The Budapest office of Gide Loyrette Nouel is advising the Servier Group on the voluntary public offer to purchase all outstanding shares in its majority-owned subsidiary Egis Pharmaceuticals Plc.
Servier Group, a privately held and research-led pharmaceutical group with global turnover of €3.9 billion in 2012, has owned a majority stake of approximately 51% in Egis since 1995. Servier Group is primarily an innovation-led pharmaceutical group, but also controls three generic pharmaceutical affiliates, of which Egis is one. Each subsidary operates in separate markets with its own separate management, identity and business strategy.
Egis is a leading pharmaceutical company in Central and Eastern Europe and the CIS countries, with a strong portfolio of high-quality generic pharmaceuticals.
The Offer has been submitted for approval to the Hungarian Financial Supervisory Authority.
The Gide Loyrette Nouel team was led by partner François d'Ornano and was composed of local partner Akos Kovach, Csaba Ember and Ioana Knoll-Tudor.
